IRulya Therapeutics Inc. IRLA
33.16 USD -0.39 (-1.16%)
At close·Nov 4, 2026, 6:45 AM EST
31.50 -1.66 -5.01%
Pre-market · Nov 4, 6:45 AM ET
15.10 52-week range 910.00
- YTD
- -95.05%
- 1 year
- -89.83%
Altman Z-Score
-5.16 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C-1 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 4
P/E -2.0×
P/S 0.0×
P/B -4.7×
P/FCF -4.0×
EV/EBITDA -2.2×
EV/Sales 0.0×
FCF Yield -24.9%
Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
ROE 235.1%
ROIC -73.7%
ROA -89.8%
Revenue 0.0%
Operating Income 12.0%
EPS (diluted) -28.2%
Free Cash Flow -29.9%
Current Ratio 0.5×
Quick Ratio 0.5×
Debt / Equity -0.5×
Net Debt / EBITDA -0.2×
Interest Coverage 0.0×
Dividend Yield 0.0%
Payout Ratio 0.0%
Annual · latest fiscal year ends 2025-12-31
